ELAN
Elanco Animal Health Incorporated
$19.03
-$0.17(-0.89%)
67
Overall
80
Value
54
Tech
--
Quality
Market Cap
$9.54B
Volume
6.16M
52W Range
$8.02 - $19.27
Target Price
$18.44
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | $3.1B | $3.1B | $3.3B | $4.8B | $4.4B | $4.4B | $4.4B | ||
| Total Revenue | $3.1B | $3.1B | $3.3B | $4.8B | $4.4B | $4.4B | $4.4B | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | $1.6B | $1.5B | $1.7B | $2.1B | $1.9B | $1.9B | $2.0B | ||
| GROSS PROFIT | |||||||||
| Gross Profit | $1.5B | $1.6B | $1.6B | $2.6B | $2.5B | $2.5B | $2.4B | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $1.2B | $1.2B | $1.7B | $2.3B | $2.1B | $2.2B | $2.2B | ||
| Research & Development | $246.6M | $270.1M | $327.0M | $369.0M | $321.0M | $327.0M | $344.0M | ||
| Research Expense | -- | -- | -- | $369.0M | $321.0M | $327.0M | $344.0M | ||
| Selling, General & Administrative | $735.2M | $760.2M | $996.0M | $1.4B | $1.3B | $1.3B | $1.3B | ||
| Selling & Marketing Expenses | -- | -- | -- | $248.0M | $201.0M | $207.0M | $236.0M | ||
| General & Administrative Expenses | -- | -- | -- | $1.4B | $1.3B | $1.3B | $1.3B | ||
| Salaries & Wages | -- | -- | -- | $-29.0M | -- | -- | -- | ||
| Depreciation & Amortization | $197.4M | $200.4M | $360.0M | $556.0M | $528.0M | $548.0M | $527.0M | ||
| Depreciation & Amortization | $197.4M | $200.4M | $360.0M | $556.0M | $528.0M | $548.0M | $527.0M | ||
| Amortization | $197.4M | $200.4M | $360.0M | $556.0M | $528.0M | $548.0M | $527.0M | ||
| Other Operating Expenses | -- | -- | -- | -- | $-3.0M | $75.0M | $18.0M | ||
| OPERATING INCOME | |||||||||
| Operating income | $313.8M | $370.0M | $-77.0M | $304.0M | $384.0M | $251.0M | $233.0M | ||
| EBITDA | $439.7M | $472.2M | $-10.0M | $381.0M | $169.0M | $-501.0M | $1.1B | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | $29.6M | $78.9M | $150.0M | $236.0M | $241.0M | $277.0M | -- | ||
| Intinc | -- | -- | -- | -- | -- | $4.0M | $31.0M | ||
| Net Non-Operating Interest Income/Expense | $-29.6M | $-78.9M | $-150.0M | $-236.0M | $-241.0M | $4.0M | $31.0M | ||
| Gain on Sale of Securities | -- | -- | -- | $-10.0M | $-8.0M | -- | -- | ||
| Other Income/Expense | $170.1M | $212.9M | $445.0M | $5.0M | $-215.0M | $32.0M | $-640.0M | ||
| Other Special Charges | $-41.3M | $-27.4M | $178.0M | $-5.0M | $-32.0M | $-75.0M | -- | ||
| SPECIAL ITEMS | |||||||||
| Restructring And Mn A Income | $128.8M | $185.5M | $623.0M | $634.0M | $183.0M | $127.0M | $150.0M | ||
| Special Income Charges | $-128.8M | $-185.5M | $-623.0M | $-634.0M | $-183.0M | $-1.2B | $-150.0M | ||
| Impairment of Capital Assets | $-81.9M | $-32.6M | $-36.0M | -- | -- | $1.0B | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $143.7M | $157.1M | $-527.0M | $-335.0M | $169.0M | $-1.2B | $488.0M | ||
| Pre-Tax Income | $114.1M | $78.2M | $-672.0M | $-571.0M | $-72.0M | $-1.2B | $488.0M | ||
| INCOME TAX | |||||||||
| Tax Provision | $27.6M | $10.3M | $-103.0M | $-88.0M | $6.0M | $36.0M | $150.0M | ||
| NET INCOME | |||||||||
| Net Income | $86.5M | $67.9M | $-574.0M | $-483.0M | $-78.0M | $-1.2B | $338.0M | ||
| Net Income (Continuing Operations) | $86.5M | $67.9M | $-560.0M | $-483.0M | $-78.0M | $-1.2B | $338.0M | ||
| Net Income (Discontinued Operations) | $86.5M | $67.9M | $-574.0M | $-483.0M | $-78.0M | $-1.2B | $338.0M | ||
| Net Income (Common Stockholders) | $86.5M | $67.9M | $-574.0M | $-483.0M | $-78.0M | $-1.2B | $338.0M | ||
| Normalized Income | $162.7M | $359.4M | $208.0M | -- | -- | -- | $-365.9M | ||
| TOTALS | |||||||||
| Total Expenses | $2.8B | $2.7B | $3.4B | $4.5B | $4.0B | $4.2B | $4.2B | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $313.7M | $369.0M | $441.4M | $487.2M | $488.3M | $492.3M | $494.0M | ||
| Average Shares Outstanding (Diluted) | $313.7M | $370.3M | $441.4M | $487.2M | $488.3M | $492.3M | $497.3M | ||
| Shares Outstanding | $365.6M | $398.5M | $472.2M | $473.2M | $491.5M | $493.0M | $494.6M | ||
| Basic EPS | $0.28 | $0.18 | $-1.27 | $-0.97 | $-0.16 | $-2.5 | $0.68 | ||
| Basic EPS (Continuing Operations) | $0.28 | $0.18 | $-1.27 | $-0.97 | $-0.16 | $-2.5 | $0.68 | ||
| Diluted EPS | $0.28 | $0.18 | $-1.27 | $-0.97 | $-0.16 | $-2.5 | $0.68 | ||
| Diluted EPS (Continuing Operations) | $0.28 | $0.18 | $-1.27 | $-0.97 | $-0.16 | $-2.5 | $0.68 | ||
| OTHER METRICS | |||||||||
| Acquisition Expense | -- | -- | -- | -- | $105.0M | $93.0M | $18.0M | ||
| Gain On Sale Of Business | -- | -- | -- | $-1.0M | $3.0M | -- | $640.0M | ||
| Gain On Sale Of P P E | $800.0K | -- | $4.0M | -- | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | $-41.0M | $-4.0M | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | $-221.0M | $-266.0M | $-379.0M | $-296.0M | ||
| Marketing Expense | -- | -- | -- | $248.0M | $201.0M | $207.0M | $236.0M | ||
| Net Income Discontinuous Operations | -- | -- | -- | $-325.0M | $-25.0M | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | $10.0M | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | $-284.0M | $-21.0M | -- | -- | ||
| Other Gand A | -- | -- | -- | $1.4B | $1.3B | $1.3B | $1.3B | ||
| Other Impairment Of Capital Assets | -- | -- | -- | $66.0M | $81.0M | $32.0M | $81.0M | ||
| Write Down | -- | -- | -- | $-64.0M | $-3.0M | $-3.0M | $-458.0M | ||
| Othspecchg | -- | -- | $-15.0M | -- | -- | -- | -- | ||
| Restruct | $128.8M | $185.5M | $623.0M | $634.0M | $183.0M | $127.0M | $150.0M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ELAN | $19.03 | -0.9% | 6.16M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Elanco Animal Health Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW